TrialBritish journal of cancer2011

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.

G Procopio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.